Work

Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis

Year: 2016

Type: article

Abstract: Myelofibrosis (MF) is a clonal Philadelphia negative myeloproliferative neoplasm that is associated with cytopenias, splenomegaly, a heterogeneous symptom profile, and decreased overall survival.[1][1] Accurate prognostication of MF is essential for clinical decision making, as survival estimates

Source: Haematologica

DOI: 10.3324/haematol.2016.149013

Authors: K. Gowin, M. Coakley, H. Kosiorek, R. Mesa

Institutions: Mayo Clinic in Arizona, Cork University Hospital

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,157